MEK inhibitors for the treatment of non-small cell lung cancer

BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the proliferation, differentiation, and apoptosis of tumor cells by activating the RAS/RAF/MEK/ERK...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hematology and oncology Vol. 14; no. 1; pp. 1 - 12
Main Authors: Han, Jing, Liu, Yang, Yang, Sen, Wu, Xuan, Li, Hongle, Wang, Qiming
Format: Journal Article
Language:English
Published: London BioMed Central 05.01.2021
BioMed Central Ltd
Springer Nature B.V
BMC
Subjects:
Amino acids
Antimitotic agents
Antineoplastic agents
Apoptosis
Binding sites
Cancer
Cancer Research
Cancer therapies
Cell differentiation
Cell proliferation
Chemotherapy
Diarrhea
Drug resistance
Drug therapy
Epidermal growth factor
Extracellular signal-regulated kinase
FDA approval
Gene mutations
Genetic aspects
Health aspects
Hematology
Hypertension
Immune checkpoint inhibitors
Immunosuppressive agents
Kinases
Lung cancer
Lung cancer, Non-small cell
Lung cancer, Small cell
MAP kinase
Medical prognosis
Medical research
Medicine
Medicine & Public Health
Medicine, Experimental
MEK
MEK inhibitors
Metastasis
Mutation
Neutropenia
Non-small cell lung cancer
Non-small cell lung carcinoma
Oncology
Patients
Protein-tyrosine kinase
Proteins
RAF
Raf protein
RAS
Review
Schedules
Signal transduction
Small cell lung carcinoma
Targeted therapy
Tumor cells
Tyrosine
Vomiting
MEK
Targeted therapy
RAS
MEK inhibitors
RAF
ERK signaling pathway
Non-small cell lung cancer
ISSN:1756-8722, 1756-8722
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the proliferation, differentiation, and apoptosis of tumor cells by activating the RAS/RAF/MEK/ERK signaling pathway. To date, agents that target RAS/RAF/MEK/ERK signaling pathway have been investigated in NSCLC patients harboring BRAF mutations. BRAF and MEK inhibitors have gained approval for the treatment of patients with NSCLC. According to the reported findings, the combination of MEK inhibitors with chemotherapy, immune checkpoint inhibitors, epidermal growth factor receptor-tyrosine kinase inhibitors or BRAF inhibitors is highly significant for improving clinical efficacy and causing delay in the occurrence of drug resistance. This review summarized the existing experimental results and presented ongoing clinical studies as well. However, further researches need to be conducted to indicate how we can combine other drugs with MEK inhibitors to significantly increase therapeutic effects on patients with lung cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1756-8722
1756-8722
DOI:10.1186/s13045-020-01025-7